Investigational drug · Phase 2
PA9159 Metered-Dose
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bronchial Asthma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "PA9159 Metered-Dose"
First trial start
2025
Feb 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PA9159 Metered-Dose", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchial Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "PA9159 Metered-Dose" as an intervention, largest first.
- Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic RhinitisPivotal-lookingCompleted
Anhui Palo Alto Pharmaceuticals, Inc.Industry
NCT05234580 · 204 participants · Start Apr 15, 2022 · Primary completion Oct 10, 2022
Drug: PA9159 nasal spray solution, 10 μg once daily for 14 days; PA9159 nasal spray solution, 20 μg once daily for 14 days and 2 more · For: Allergic Rhinitis
Sites: Bengbu, China; Hefei, China; Beijing, China · 17 sites in all
- Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial AsthmaRecruiting
Anhui Palo Alto Pharmaceuticals, Inc.Industry
NCT07326995 · 60 participants (planned) · Start Feb 24, 2025 · Primary completion Feb 2026
Drug: PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days; PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days and 2 more · For: Bronchial Asthma
Sites: Nanchang, China
Anhui Palo Alto Pharmaceuticals, Inc.Industry
NCT05170763 · 60 participants · Start Nov 10, 2021 · Primary completion Jan 5, 2022
Drug: PA9159 nasal spray solution, 10 μg one day treatment; PA9159 nasal spray solution, 20 μg one day treatment and 5 more · For: Allergic Rhinitis
Sites: Beijing, China
Anhui Palo Alto Pharmaceuticals, Inc.Industry
NCT07345442 · 36 participants · Start Mar 14, 2025 · Primary completion Jun 9, 2025
Drug: PA9159 nasal spray solution, 80 μg one day treatment; PA9159 nasal spray solution, 160 μg one day treatment and 5 more · For: Allergic Rhinitis
Sites: Nanchang, China
Anhui Palo Alto Pharmaceuticals, Inc.Industry
NCT07324707 · 30 participants (planned) · Start Oct 15, 2025 · Primary completion Mar 2026
Drug: PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days; Fluticasone Propionate Inhaled Aerosol 200 μg per day for 28 days · For: Bronchial Asthma
Sites: Nanchang, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bronchial Asthma
- per day for 28 daysPhase 22 trials
Anhui Palo Alto Pharmaceuticals, Inc. · Bronchial Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.